Compare AGBK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | PHVS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Brazil | Switzerland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | AGBK | PHVS |
|---|---|---|
| Price | $9.89 | $26.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $17.20 | ★ $40.70 |
| AVG Volume (30 Days) | ★ 524.5K | 101.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.00 | $11.51 |
| 52 Week High | $12.21 | $29.80 |
| Indicator | AGBK | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 51.12 |
| Support Level | $9.00 | $24.25 |
| Resistance Level | $12.12 | $28.90 |
| Average True Range (ATR) | 0.52 | 1.21 |
| MACD | -0.20 | -0.06 |
| Stochastic Oscillator | 28.48 | 54.90 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.